Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.
The annual mortality rate of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection at the Danish CF-centre ranged from 10 to 20% in the years 1970-1975. In this period the patients received antipseudomonal chemotherapy only during acute exacerbations of infection. From 1976 99 patients acquired chronic P. aeruginosa infection and were given regular and intensive antipseudomonal treatment 3-4 times per year. The patients were followed for 612 patient-years; 7 died and the 10-year survival rate after onset of P. aeruginosa infection was 90% +/- 4%. The annual mortality rate is now 1-2%. Although precipitating antibodies against P. aeruginosa increased significantly, pulmonary function did not deteriorate with duration of infection. Cross-infection between patients caused an increased incidence of chronic P. aeruginosa infection which was reduced by hygienic measures.
Pedersen
S S
SS
Department of Paediatrics, Rigshospitalet, Copenhagen, Denmark.
Jensen
T
T
Høiby
N
N
Koch
C
C
Flensborg
E W
EW
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality; D003718:Denmark; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007769:Lactams; D008171:Lung Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D012129:Respiratory Function Tests; D014031:Tobramycin / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D007769:Lactams; D014031:Tobramycin